Plus Therapeutics (PSTV) Share-based Compensation (2010 - 2026)
Plus Therapeutics (PSTV) reported Share-based Compensation of $1.0 million for Q1 2026, up 590.54% year-over-year from $148000.0 in Q1 2025, and up 43.34% quarter-over-quarter from $713000.0 in Q4 2025.
Plus Therapeutics (PSTV) Share-based Compensation (2010 - 2026) Analysis & Trends
Plus Therapeutics (PSTV) has 17 years of Share-based Compensation data on file, last reported at $1.0 million in Q1 2026.
- Share-based Compensation for Q1 2026 came in at $1.0 million, up 590.54% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.4 million (up 337.32% YoY), and the FY2025 annual result was $1.5 million, up 180.0% from the prior year.
- Share-based Compensation climbed to $1.0 million in Q1 2026 per PSTV's latest filing, from $713000.0 in the prior quarter.
- Over five years, Share-based Compensation peaked at $1.0 million in Q1 2026 and troughed at $125000.0 in Q3 2024.
- A 5-year average of $252176.5 and a median of $148000.0 in 2023 frame the typical range for Share-based Compensation.
- The sharpest annual moves came in 2022 and 2026: Share-based Compensation fell 28.33% in 2022, then surged 590.54% in 2026.
- A 5-year view of Share-based Compensation shows it stood at $130000.0 in 2022, then gained by 8.46% to $141000.0 in 2023, then retreated by 9.22% to $128000.0 in 2024, then surged by 457.03% to $713000.0 in 2025, then surged by 43.34% to $1.0 million in 2026.
- Business Quant data shows PSTV's Share-based Compensation at $1.0 million in Q1 2026, $713000.0 in Q4 2025, and $527000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | - |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | 305,000.00 |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 166.40 Mn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | 26.47 Mn |
| 10 | Plus Therapeutics | 34.26 Mn | 19.15 Mn | - | 1.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.02 Mn |
| Mar 31, 2026 | 1.02 Mn |
| Dec 31, 2025 | 713,000.00 |
| Dec 31, 2025 | 713,000.00 |
| Sep 30, 2025 | 527,000.00 |
| Sep 30, 2025 | 527,000.00 |
| Jun 30, 2025 | 152,000.00 |
| Jun 30, 2025 | 152,000.00 |
| Mar 31, 2025 | 148,000.00 |
| Mar 31, 2025 | 148,000.00 |
| Dec 31, 2024 | 128,000.00 |
| Dec 31, 2024 | 128,000.00 |
| Sep 30, 2024 | 125,000.00 |
| Sep 30, 2024 | 125,000.00 |
| Jun 30, 2024 | 151,000.00 |
| Jun 30, 2024 | 151,000.00 |
| Mar 31, 2024 | 146,000.00 |
| Mar 31, 2024 | 146,000.00 |
| Dec 31, 2023 | 141,000.00 |
| Dec 31, 2023 | 141,000.00 |